Thymosin Alpha-1 Dosing & Protocols — Research Reference

Thymosin alpha-1 (Tα1) is a 28-amino-acid acetylated peptide originally isolated from thymic fraction 5. It is the most-characterized member of the alpha-thymosin family and is studied extensively in immune-modulation and antiviral research models.

Reconstitution for Research

Tα1 is typically supplied lyophilized in 1.6 mg or 5 mg vials. A 1.6 mg vial reconstituted with 1 mL bacteriostatic water yields 1.6 mg/mL; 10 IU on a U-100 syringe at that concentration delivers 160 mcg. Refrigerate at 2–8 °C and use within the COA's documented window.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Standard immune-research | 1.6 mg per dose, 2× per week | Most cited tier across infection and immune-recovery research | | Antiviral research | 1.6 mg per dose, daily for 4 weeks | Loading-phase pattern in viral-clearance studies | | Combination immuno-oncology research | 1.6 mg, 2× per week | Adjunct dosing pattern alongside conventional therapy in published trials |

Scheduling

Subcutaneous injection is the most-cited route. The twice-weekly cadence (typically Monday/Thursday) is the dominant pattern in published clinical and translational research. Cycle duration ranges from 4 weeks (acute viral models) to 6+ months (chronic immune-restoration studies).

Mechanism Context for Dose Selection

Tα1 signals primarily through Toll-like receptor 9 (TLR9) and TLR2 on dendritic cells and other innate immune populations. The signal restores Th1-skewed responses, NK-cell function, and dendritic-cell maturation in immune-suppressed states. The dose tiers above reflect the receptor occupancy and downstream cytokine profiles documented in published dose-finding work.

Stability Considerations

Reconstituted Tα1 in bacteriostatic water is stable refrigerated for the COA-documented window (typically 14–30 days). The acetylated N-terminus contributes to peptidase resistance vs unmodified thymosin fragments.

Quality and Identity Verification

LC-MS confirmation of molecular weight (3108.39 Da) and HPLC purity ≥98% are the standard acceptance criteria.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.

References

1. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593–608.
2. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232–4239.
3. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019;9:873.